Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI-enhanced online adaptive radiotherapy by virtual integration of a standalone MRI simulator and CBCT-based treatment delivery.

Radiation oncology (London, England)·2026
Same author

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes.

Journal of cutaneous pathology·2026
Same author

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Decision making in intrathecal therapy for leptomeningeal disease.

Oncology·2026
Same author

Melanoma in older patients in Switzerland: A comparison across age groups including patients over the age of 80 years.

Cancer epidemiology·2026
Same author

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Current oncology (Toronto, Ont.)·2026
Same journal

Exploration of the radiation dose-toxicity relationship for multiple ophthalmological organs at risk for pediatric patients assessed in long-term head and neck rhabdomyosarcoma survivors.

Clinical and translational radiation oncology·2026
Same journal

Skin Cosmesis assessment tools and methods in patients with non-melanoma skin cancers treated with radiotherapy: Systematic review on behalf of the ESTRO skin and soft tissue focus group and the GEC-ESTRO head and neck and skin working group.

Clinical and translational radiation oncology·2026
Same journal

Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy.

Clinical and translational radiation oncology·2026
Same journal

Moving beyond anatomy: the future of rectal cancer management is biologically-informed, response-adapted, and patient-centered.

Clinical and translational radiation oncology·2026
Same journal

Organ preservation in rectal cancer following clinical complete response after short-course radiotherapy-based total neoadjuvant therapy.

Clinical and translational radiation oncology·2026
Same journal

Radiotherapy quality assurance in the PRO-GLIO trial: results from a dummy run comparing experts across twelve institutions in two Scandinavian countries.

Clinical and translational radiation oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
11:24

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

Published on: October 18, 2011

15.1K

First-in-human e-Flash radiotherapy using a modified conventional C-arm linear accelerator.

Jens von der Grün1, Riccardo Dal Bello1, Serena Psoroulas1

  • 1Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Clinical and Translational Radiation Oncology
|October 13, 2025
PubMed
Summary
This summary is machine-generated.

This study presents the first patient treated with e-Flash (ultra-high dose rate) radiotherapy using a modified conventional linear accelerator. The treatment showed a good tumor response with no severe toxicity, demonstrating the safety of this novel approach.

Keywords:
Clinical translationDosimetryElectronsFlash-RTMalignant melanomaUHDR

More Related Videos

Use of a Linear Accelerator for Conducting In Vitro Radiobiology Experiments
06:08

Use of a Linear Accelerator for Conducting In Vitro Radiobiology Experiments

Published on: May 26, 2019

7.9K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.9K

Related Experiment Videos

Last Updated: Jan 15, 2026

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
11:24

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

Published on: October 18, 2011

15.1K
Use of a Linear Accelerator for Conducting In Vitro Radiobiology Experiments
06:08

Use of a Linear Accelerator for Conducting In Vitro Radiobiology Experiments

Published on: May 26, 2019

7.9K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.9K

Area of Science:

  • Radiation Oncology
  • Medical Physics

Background:

  • The FLASH effect aims to improve cancer treatment by sparing normal tissues at ultra-high dose rates while maintaining tumor control.
  • Conventional linear accelerators are being adapted for ultra-high dose rate (UHDR) electron beam delivery for research purposes.

Purpose of the Study:

  • To report the first-in-human safety and feasibility data of e-Flash radiotherapy delivered by a modified conventional linear accelerator.
  • To evaluate the initial tumor response and toxicity in a patient treated with e-Flash electron beams.

Main Methods:

  • A conventional Varian TrueBeam linear accelerator was modified to deliver 9 MeV UHDR electron beams.
  • A single patient with melanoma lesions was treated under an approved Phase I trial protocol (NCT06549439).
  • The patient received 3 fractions of 9 Gy, with the first two delivered via e-Flash and the third via conventional electrons, monitored by in-vivo dosimetry.

Main Results:

  • e-Flash fractions were successfully delivered as per the treatment protocol.
  • In-vivo dosimetry confirmed accurate dose delivery.
  • The patient exhibited a good tumor response with no severe or unexpected toxicity observed up to six weeks post-treatment.

Conclusions:

  • This study demonstrates the first successful clinical application of e-Flash radiotherapy using a modified conventional linear accelerator.
  • Adapting conventional linear accelerators for e-Flash delivery can expedite clinical trials for Flash radiotherapy.